AGCT develops a groundbreaking PCR-based assay technology that will…
non-invasive liquid biopsy testing
by detecting cancer earlier
through earlier and faster decision-making in treatment selection
in any molecular diagnostic laboratory
Highest discrimination of mutant vs wild-type DNA molecules
Exclusion PCR amplifies the mutant target sequence only in each cycle
Can be run in any MDx laboratory using existing PCR equipment
Technology will be developed across MDx platforms